trending Market Intelligence /marketintelligence/en/news-insights/trending/5e3xjo_p_up_hpkfpzqywa2 content esgSubNav
In This List

Corbus appoints former US FDA official to board

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Corbus appoints former US FDA official to board

Norwood, Mass.-based Corbus Pharmaceuticals Holdings Inc. appointed John Jenkins to its board.

Jenkins is a former director of the Office of New Drugs at the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, having served in the role from 2002 to 2017. During his time at the FDA, he was responsible for reviewing new drug applications and biological licensing applications and approval of new molecular entities.

He is expected to help Corbus advance its cystic fibrosis drug lenabasum to potential regulatory approval.